Aspergillus flavus induces granulomatous cerebral aspergillosis in mice with display of distinct cytokine profile

Cytokine

Volumn 72, Issue 2, 2015, Pages 166-172

  Anand, R ^a   Shankar, J ^b   Tiwary, B N ^c   Singh, A P ^a  

^a NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

^b JAYPEE UNIVERSITY OF INFORMATION TECHNOLOGY   (India)

^c GURU GHASIDAS UNIVERSITY   (India)

Author keywords

Aspergillus flavus; Cerebral aspergillosis; Cytokines; Granuloma; Neuropathogenesis

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 23P40; INTERLEUKIN 4; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; INTERLEUKIN 12P40;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FLAVUS; BRAIN HOMOGENATE; BRAIN NERVE CELL; BRAIN TISSUE; CENTRAL NERVOUS SYSTEM ASPERGILLOSIS; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FUNGUS HYPHAE; GRANULOMA; HISTOPATHOLOGY; IMMUNE RESPONSE; ISCHEMIA; MALE; MORTALITY; MOUSE; NERVE CELL NECROSIS; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PATHOGENICITY; ANIMAL; BAGG ALBINO MOUSE; BRAIN; DISEASE MODEL; IMMUNOLOGY; ISOLATION AND PURIFICATION; KINETICS; METABOLISM; NERVE CELL; PATHOLOGY;

ASPERGILLUS; ASPERGILLUS FLAVUS; MURINAE; MUS;

ANIMALS; ASPERGILLUS FLAVUS; BRAIN; CYTOKINES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GRANULOMA; INTERFERON-GAMMA; INTERLEUKIN-12; INTERLEUKIN-12 SUBUNIT P40; INTERLEUKIN-17; INTERLEUKIN-23; INTERLEUKIN-4; INTERLEUKIN-6; KINETICS; MICE; MICE, INBRED BALB C; NEUROASPERGILLOSIS; NEURONS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84922042286     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2015.01.006     Document Type: Article

References (33)

1. Denning D.W. Invasive aspergillosis. Clin Infect Dis 1993, 26:781-803.
2. Morgan J., Wannemuehler K.A., Marr K.A., Hadley S., Kontoyiannis D.P., Walsh T.J., et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 2005, 43:S49-S58.
3. Ford S., Friedman L. Experimental study of the pathogenicity of aspergilli for mice. J Bacteriol 1967, 94:928-933.
4. Mosquera J., Warn P.A., Morrissey J., Moore C.B., Gil-Lamaignere C., Denning D.W. Susceptibility testing of Aspergillus flavus: inoculum dependence with itraconazole and lack of correlation between susceptibility to amphotericin B in vitro and outcome in vivo. Antimicrob Agents Chemother 2001, 45:1456-1462.
5. Kamai Y., Harasaki T., Fukuoka T., Ohya S., Uchida K., Yamaguchi H., et al. In vitro and in vivo activities of CS-758 (R-120758), a new triazole antifungal agent. Antimicrob Agents Chemother 2002, 46:367-370.
6. Bodey G., Bueltmann B., Duguid W., Gibbs D., Hanak H., Hotchi M., et al. Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis 1992, 11:99-109.
7. Rudwan M.A., Sheikh H.A. Aspergilloma of paranasal sinuses - a common cause of unilateral proptosis in Sudan. Clin Radiol 1976, 27:497-502.
8. Hussain S., Salahuddin N., Ahmad I., Salahuddin I., Jooma R. Rhinocerebral invasive mycosis: occurrence in immunocompetent individuals. Eur J Radiol 1995, 20:151-155.
9. Panda N.K., Sharma S.C., Chakrabarti A., Mann S.B. Paranasal sinus mycoses in north India. Mycoses 1998, 41:281-286.
10. Alrajhi A.A., Enani M., Mahasin Z., Al-Omran K. Chronic invasive aspergillosis of the paranasal sinuses in immunocompetent hosts from Saudi Arabia. Am J Trop Med Hyg 2001, 65:83-86.
11. Roncati L., Barbolini G., Fano R.A., Rivasi F. Fatal Aspergillus flavus infection in a neonate. Fetal Pediatr Pathol 2010, 29:239-244.
12. Saghrouni F., Ben Y.Y., Gheith S., Bouabid Z., Ben A.J., Khammari I., et al. Twenty-nine cases of invasive aspergillosis in neutropenic patients. Med Mal Infect 2011, 41:657-662.
13. Beal M.F., O'Carroll P., Kleinman G.M., Grossman R.I. Aspergillosis of the nervous system. Neurology 1982, 32:473-479.
14. Jinkins J.R., Siqueira E., Al-Kawi M.Z. Cranial manifestations of aspergillosis. Neuroradiology 1987, 29:181-185.
15. Epstein N.E., Hollingsworth R., Black K., Farmer P. Fungal brain abscesses (aspergillosis/mucormycosis) in two immunosuppressed patients. Surg Neurol 1991, 35:286-289.
16. Xiao B.G., Link H. Immune regulation within the central nervous system. J Neurol Sci 1998, 157:1-12.
17. Anand R., Tiwary B.N. Th1 and Th2 cytokines in a self-healing primary pulmonary Aspergillus flavus infection in BALB/c mice. Cytokine 2010, 52:258-264.
18. Anand R., Shankar J., Singh A.P., Tiwary B.N. Cytokine milieu in renal cavities of immunocompetent mice in response to intravenous challenge of Aspergillus flavus leading to aspergillosis. Cytokine 2013, 61:63-70.
19. Dupont B. Fungal infections of the central nervous system. Clinical mycology 2003, 539-553. Churchill Livinstone, New York, USA. 2nd ed. E.J. Anaissie, M.R. McGinnis, M.A. Pfaller (Eds.).
20. Lee S.C., Dickson D.W., Casadevall A. Pathology of cryptococcal meningoencephalitis: analysis of 27 patients with pathogenetic implications. Hum Pathol 1996, 27:839-847.
21. Rock R.B., Gekker G., Hu S., Sheng W.S., Cheeran M., Lokensgard J.R., et al. Role of microglia in central nervous system infections. Clin Microbiol Rev 2004, 17:942-964.
22. Decken K., Kohler G., Palmer-Lehmann K., Wunderlin A., Mattner F., Magram J., et al. Interleukin-12 is essential for a protective Th1 response in mice infected with Cryptococcus neoformans. Infect Immun 1998, 66:4994-5000.
23. Maffei C.M., Mirels L.F., Sobel R.A., Clemons K.V., Stevens D.A. Cytokine and inducible nitric oxide synthase mRNA expression during experimental murine cryptococcal meningoencephalitis. Infect Immun 2004, 72:2338-2349.
24. Town T., Nikolic V., Jun T. The microglial "activation" continuum: from innate to adaptive responses. J Neuroinflammation 2005, 2:24.
25. Gadient R.A., Otten U.H. Interleukin-6 (IL-6) a molecule with both beneficial and destructive potentials. Prog Neurobiol 1997, 52:379-390.
26. Paul R., Koedel U., Winkler F., Kieseier B.C., Fontana A., Kopf M., et al. Lack of IL-6 augments inflammatory response but decreases vascular permeability in bacterial meningitis. Brain 2003, 126:1873-1882.
27. Houssiau F.A., Bukasa K., Sindic C.J., Van Damme J., Van Snick J. Elevated levels of the 26K human hybridoma growth factor (interleukin 6) in cerebrospinal fluid of patients with acute infection of the central nervous system. Clin Exp Immunol 1988, 71:320-323.
28. Matsuzono Y., Narita M., Akutsu Y., Togashi T. Interleukin-6 in cerebrospinal fluid of patients with central nervous system infections. Acta Paediatr 1995, 84:879-883.
29. Koedel U., Bernatowicz A., Frei K., Fontana A., Pfister H.W. Systemically (but not intrathecally) administered IL-10 attenuates pathophysiologic alterations in experimental pneumococcal meningitis. J Immunol 1996, 157:5185-5191.
30. Frei K., Leist T., Meager A., Gallo P., Leppert D., Zinkernagel R., et al. Production of B cell stimulatory factor-2 and interferon gamma in the central nervous system during viral meningitis and encephalitis. J Exp Med 1988, 168:449-453.
31. Grau G.E., Frei K., Piguet P.F., Fontana A., Heremans H., Billiau A., et al. Interleukin 6 production in experimental cerebral malaria: modulation by anti-cytokine antibodies and possible role in hypergammaglobulinemia. J Exp Med 1990, 172:1505-1508.
32. Erta M., Quintana A., Hidalgo J. Interleukin-6, a major cytokine in the central nervous system. Int J Biol Sci 2012, 8:1254-1266.
33. Jones S.A. Directing transition from innate to acquired immunity: defining a role for IL-6. J Immunol 2005, 175:3463-3468.